FibroGen (FGEN) Stock Price, News & Analysis

Company Overview

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Key Stats

• Today's Range: $0.30 to $0.35
• 50-Day Range: $0.32 to $0.77
• 52-Week Range: $0.18 to $2.80
• Volume: 2.34 million shs
• Average Volume: 2.33 million shs
• Market Capitalization: $31.79 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Moderate Buy

FibroGen Stock Analysis - MarketRank™

FibroGen scored higher than 77% of companies evaluated by MarketBeat, and ranked 217th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

FibroGen has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

FibroGen has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for FibroGen are expected to grow in the coming year, from ($0.80) to ($0.45) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of FibroGen is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of FibroGen is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.37% of the float of FibroGen has been sold short.

Short Interest Ratio / Days to Cover

FibroGen has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in FibroGen has recently increased by 79.66%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

FibroGen does not currently pay a dividend.

Dividend Growth

FibroGen does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.84

Percentage of Shares Shorted

5.37% of the float of FibroGen has been sold short.

Short Interest Ratio / Days to Cover

FibroGen has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in FibroGen has recently increased by 79.66%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.61

News Sentiment

FibroGen has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 18 news articles for FibroGen this week, compared to 2 articles on an average week.

Search Interest

Only 4 people have searched for FGEN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 5 people have added FibroGen to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, FibroGen insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.98% of the stock of FibroGen is held by insiders.

Percentage Held by Institutions

72.71% of the stock of FibroGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

FGEN Stock Analysis - Frequently Asked Questions

How have FGEN shares performed this year?

FibroGen's stock was trading at $0.5295 at the beginning of 2025. Since then, FGEN shares have decreased by 40.5% and is now trading at $0.3150.
View the best growth stocks for 2025 here.

How were FibroGen's earnings last quarter?

FibroGen, Inc. (NASDAQ:FGEN) announced its earnings results on Monday, March, 17th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.08). The biopharmaceutical company earned $3.14 million during the quarter, compared to analyst estimates of $24.91 million.

When did FibroGen IPO?

FibroGen (FGEN) raised $146 million in an IPO on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

Who are FibroGen's major shareholders?

Top institutional investors of FibroGen include Primecap Management Co. CA (4.58%), Renaissance Technologies LLC (1.35%), Marshall Wace LLP (1.26%) and Geode Capital Management LLC (1.05%). Insiders that own company stock include Thane Wettig, Christine Chung, Mark Eisner, Deyaa Adib, James A Schoeneck, Juan Graham and Benjamin Cravatt.
View institutional ownership trends.

How do I buy shares of FibroGen?

Shares of FGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of FibroGen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that FibroGen investors own include Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR), The RMR Group (RMR), iShares Micro-Cap ETF (IWC) and AUO (AUOTY).

Company Calendar

• Last Earnings: 3/17/2025
• Today: 3/23/2025
• Next Earnings (Estimated): 5/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:FGEN
• CIK: 921299
• Web: www.fibrogen.com
• Phone: (415) 978-1200
• Fax: 415-978-1902
• Employees: 570
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.00
• High Stock Price Target: $10.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +3,074.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-284,230,000.00
• Net Margins: -67.66%
• Pretax Margin: -69.56%
• Return on Equity: N/A
• Return on Assets: -36.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.28
• Quick Ratio: 1.16

Sales & Book Value

• Annual Sales: $29.62 million
• Price / Sales: 1.07
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.87) per share
• Price / Book: -0.17

Miscellaneous

• Outstanding Shares: 100,917,000
• Free Float: 98,775,000
• Market Cap: $31.79 million
• Optionable: Optionable
• Beta: 0.82